Ranbaxy Shuffles Its CEO Again, Atul Sobti Steps Down As Daiichi Sankyo Appoints New Leader
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In a span of less than 15 months, Ranbaxy - now part of Japanese pharma Daiichi Sankyo - will see a second changing of the guard, as chief executive Atul Sobti steps down and hands over the reigns to Arun Sawhney, presently serving as president of Ranbaxy's global pharmaceutical business. Sawhney's promotion to managing director is effective Aug. 20
You may also be interested in...
In A Sudden Move, Ranbaxy CFO Omesh Sethi Quits; Analysts Shocked
MUMBAI - In a surprise move, Ranbaxy CFO and President Omesh Sethi tendered his resignation after serving the company for more than two decades in various critical positions
In A Sudden Move, Ranbaxy CFO Omesh Sethi Quits; Analysts Shocked
MUMBAI - In a surprise move, Ranbaxy CFO and President Omesh Sethi tendered his resignation after serving the company for more than two decades in various critical positions
Is Ranbaxy Inching Closer To Resolution Of Its GMP Disputes With U.S. FDA?
MUMBAI - After more than two years of serious deliberations, Ranbaxy seems to be finally moving forward to resolve charges of significant manufacturing lapses leveled by U.S. FDA at two of its India-based sites